Core Viewpoint - Haisun Pharmaceutical has successfully renewed the contract for its product, Landeolol Hydrochloride Injection (50mg), and has newly included the 150mg specification in the National Medical Insurance Directory, which is expected to positively impact the company's long-term operations [1]. Group 1: Stock Performance - As of December 8, 2025, Haisun Pharmaceutical's stock closed at 52.31 yuan, up 2.09% from the previous trading day, with a total market capitalization of 6.277 billion yuan [1]. - The stock opened at 51.36 yuan, reached a high of 52.65 yuan, and a low of 51.31 yuan, with a trading volume of 2.26 billion yuan and a turnover rate of 5.28% [1]. Group 2: Product and Revenue Impact - The product Landeolol Hydrochloride Injection (50mg) has a reimbursement price of 168 yuan per unit, while the 150mg specification is set at 389.55 yuan per unit, with the same payment scope [1]. - The agreement for these products is effective from January 1, 2026, to December 31, 2027 [1]. - In 2024, the sales revenue from the 50mg specification is projected to be 337.77 million yuan, accounting for 67.27% of the company's total revenue [1]. - The renewal of the 50mg specification is not expected to affect performance, while the inclusion of the 150mg specification is anticipated to have a positive long-term impact on operations [1].

Core Viewpoint - Jiahe Biotech-B (06998.HK) announced that its drug Lairosili (GB491) has been included in the National Medical Insurance Drug List (2025) released by the National Healthcare Security Administration on December 7, 2025, marking its first inclusion in the national medical insurance drug list [1] Group 1 - Lairosili (GB491) is a novel, highly selective oral CDK4/6 inhibitor indicated for adult patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer [1] - The new National Medical Insurance Drug List will take effect on January 1, 2026 [1] - The inclusion of Lairosili (GB491) in the medical insurance list is expected to significantly enhance patient accessibility to the drug and reduce their financial burden [1] Group 2 - The company believes that the inclusion in the insurance list will accelerate the commercialization process and market penetration of Lairosili (GB491), further boosting innovation returns [1]

Core Viewpoint - The announcement highlights that Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s subsidiary, Beijing Yiling Pharmaceutical Co., Ltd., has successfully negotiated to include its product, Qifang Bitong Pian, in the National Medical Insurance Directory for 2025, which is expected to positively impact the company's market promotion and sales scale [1][2]. Group 1: Product Inclusion in National Medical Insurance - Qifang Bitong Pian is a proprietary product developed by the company, classified as a Class 1 traditional Chinese medicine, specifically for treating persistent allergic rhinitis [1]. - The product has been assigned a medical insurance payment standard of 1.78 yuan per tablet, with a validity period for the agreement from January 1, 2026, to December 31, 2027 [1]. - The company holds complete intellectual property rights for Qifang Bitong Pian, which received its drug registration certificate from the National Medical Products Administration in January 2025 [1]. Group 2: Impact on Company Operations - In addition to Qifang Bitong Pian, the company has 11 other proprietary products included in the National Medical Insurance Directory for 2025, which may enhance the company's market presence and sales [2]. - The inclusion of these 12 proprietary traditional Chinese medicine products in the insurance directory is expected to have a positive long-term impact on the company's operational development, although the short-term effects on financial performance are currently uncertain [2].

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. announced that its product, methylphenidate hydrochloride sustained-release capsules, has been included in the National Medical Insurance Directory for 2025, which will positively impact the company's market promotion and sales [1] Group 1: Product Information - The product included is methylphenidate hydrochloride sustained-release capsules, classified under code XN06B, used for treating Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 and above [1] - The inclusion in the National Medical Insurance Directory means that the product will be reimbursed under Category B during the agreement period [1] Group 2: Market Impact - The inclusion of the product in the National Medical Insurance Directory is expected to enhance market promotion and sales, leading to a positive impact on the company's operating performance [1] - The new National Medical Insurance Directory will officially take effect on January 1, 2026, and is not expected to have a significant impact on the company's performance for the current fiscal year [1]

Core Viewpoint - The announcement highlights that Xuanzhu Biotechnology, a subsidiary of Four环医药, has successfully included its innovative drug Pirlosilib Tablets (brand name: XuanYueNing®) in the 2025 National Basic Medical Insurance Directory, which will be implemented on January 1, 2026 [1] Group 1 - The inclusion of XuanYueNing® in the National Basic Medical Insurance Directory will enhance its affordability and accessibility for patients [1] - This development is expected to promote the market penetration and increase sales scale of the drug, positively impacting the long-term operational growth of Xuanzhu Biotechnology [1] - Xuanzhu Biotechnology plans to actively cooperate in the implementation of the insurance policy, focusing on hospital access and expanding coverage in core and broader markets to improve patient access to medication [1]

Core Viewpoint - China Resources Sanjiu Pharmaceutical Co., Ltd. has successfully included its product Yiqi Qingfei Granules in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025 version) through negotiations, which is expected to enhance the company's product portfolio in the respiratory field and strengthen its market leadership position [1] Group 1 - Yiqi Qingfei Granules received the drug registration certificate from the National Medical Products Administration in January 2025 and is currently undergoing post-market academic promotion and online sales [1] - The 2025 version of the National Medical Insurance Catalog will officially take effect on January 1, 2026, marking the first inclusion of Yiqi Qingfei Granules in this catalog [1] - The short-term impact on the company's operating performance is not expected to be significant, but the inclusion is seen as a positive step for the company's strategic positioning in the respiratory product sector [1]

Core Viewpoint - China Resources Sanjiu (000999.SZ) announced that its drug Yiqi Qingfei Granules has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025 through negotiations [1] Group 1 - The inclusion of Yiqi Qingfei Granules marks a significant milestone for the company, enhancing its market access and potential revenue streams [1] - This decision is part of a broader initiative by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security to update the drug catalog [1]

Core Viewpoint - China Resources Sanjiu (000999.SZ) announced that its drug Yiqi Qingfei Granules has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025 through negotiations, as per the notice from the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] Group 1 - The inclusion of Yiqi Qingfei Granules in the National Drug Catalog marks a significant milestone for the company [1] - This development is expected to enhance the accessibility of the drug to a broader patient population under the national insurance scheme [1] - The decision reflects the government's ongoing efforts to improve healthcare coverage and access to innovative treatments [1]

四环医药(00460)发布公告，本集团旗下非全资附属公司轩竹生物科技股份有限公司(轩竹生物)自主研发 的创新药吡洛西利片(商品名：轩悦宁)首次纳入《国家基本医疗保险、生育保险和工伤保险药品目录 (2025年)》(2025国家基本医保目录)。2025国家基本医保目录将于2026年1月1日正式执行。 本次医保谈判结果有助于轩竹生物进一步提高轩悦宁在患者中的可负担性和可及性，有利于进一步推动 该药物的市场推广、提升销售规模，对轩竹生物的长期经营发展具有积极影响。轩竹生物将积极配合推 进医保政策落地，持续推进医院准入工作、拓展核心市场及广阔市场的覆盖，以期不断提升患者的用药 可及性。 ...

Core Viewpoint - The company, Hai Chen Pharmaceutical, successfully renewed the contract for its injectable Labetalol Hydrochloride (50mg) and has also included the 150mg version in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1] Group 1 - The injectable Labetalol Hydrochloride (50mg) has successfully renewed its contract [1] - The injectable Labetalol Hydrochloride (150mg) has been included for the first time in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1]